Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LNA043 in Japanese participants with knee osteoarthritis
NCT04564053Phase 1Completed
- Sponsor
- Novartis
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing LNA043 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at Day 22. Started Sep 2020; status: completed.
02
Drugs
LNA043
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04564053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04564053.